THE LIPOSOME COMPANY APPOINTS NEW MANUFACTURING EXECUTIVE
THE LIPOSOME COMPANY APPOINTS NEW MANUFACTURING EXECUTIVE PRINCETON, N.J., March 23 /PRNewswire/ -- The Liposome Company, Inc.
(NASDAQ: LIPO), announced today the appointment of Charles L. Williams to the newly created position of executive director for manufacturing. Williams, who has over 20 years of experience in pharmaceutical production, will be responsible for the manufacture of commercial products for the Liposome Company, and for the construction and operation of facilities for the production of drug supplies for the company's clinical trials.
Williams was most recently director of manufacturing for Genetics Institute, where he successfully oversaw the design, construction, and validation of an FDA-approved pharmaceutical production facility. Previously, Williams was vice president of manufacturing of Hana Corporation, and before that, he was vice president of manufacturing for Orthomatrix Corporation. From 1978 to 1985, Williams served as vice president, operations, and director of manufacturing at Collagen Corporation, where, among other accomplishments, he designed a 50,000-square-foot manufacturing facility for large volume injectible pharmaceuticals. He started his pharmaceutical career at E.R. Squibb & Sons, where he worked from 1969 to 1978, including time as manufacturing manager, parenteral manufacturing, when he was responsible for scheduling, quality and costs of a production facility that produced one million liters of finished product per year. In his new position at the Liposome Company, Williams' first task will be to direct the construction, validation and operation of a new facility, now being built, in which drug supplies for the company's clinical trials will be manufactured. The company now has three drugs in clinical trials and plans to initiate clinical studies with a fourth drug by the middle of this year. In addition, Williams will develop a strategic plan for providing production capacity as the company's products progress through the development cycle toward market launch, and he will be responsible for executing the plan, once approved. Finally, Williams will direct all aspects of the company's materials management program. "Building our drug production capabilities is a key component of our strategic plan to grow into a fully integrated pharmaceutical company," said Charles A. Baker, chairman and chief executive officer of the Liposome Company. "With three drugs making solid progress in clinical trials, and a fourth soon to move into the clinic, and with our balance sheet the strongest in the company's history, we believe the time is right to move ahead in addressing this area. Chuck Williams brings a wealth of pharmaceutical manufacturing experience, as well as an impressive track record of getting the job done. In terms of knowledge, skills and drive, we believe he is an excellent addition to our management team." Williams holds a B.S. in chemical engineering from the University of Tennessee (1969) and did graduate studies in chemical engineering at Rutgers University. He is married, has two daughters, and plans to relocate to the Princeton area. A leading company dedicated exclusively to the development of liposome and lipid-based pharmaceuticals, the Liposome Company selectively develops proprietary parenteral pharmaceuticals for the treatment, prevention and diagnosis of life-threatening illnesses. -0- 3/23/92 /CONTACT: Anne M. Van Lent, senior vice president of the Liposome Company, 609-452-7060/ (LIPO) CO: The Liposome Company, Inc. ST: New Jersey IN: MTC SU: PER
GK-AH -- NY016 -- 0449 03/23/92 09:52 EST
|Printer friendly Cite/link Email Feedback|
|Date:||Mar 23, 1992|
|Previous Article:||CEMEX SUBSIDIARY ACQUIRES PHARRIS COMPANIES|
|Next Article:||SEAGULL ENERGY ANNOUNCES ELECTION OF SENIOR VICE PRESIDENT AND CFO|